|
CNBC'S MOST SHARED
- Investing in Tech Now
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- Software Giants Rush to Cash In on Carbon Counting
- Preparing for Retirement
- What You'll See On My NASCAR Documentary Tonight
- Warren Buffett's Complete Sun Valley CNBC Interview - Transcript and Video
- Microsoft Plays a Game of Bing Pong
- How exactly does Twitter plan on making money?
- Playing by Different Rules
- Nikkei on Track to Break 6-Day Losing Streak
- GM CEO Vows Leaner and Better Company To Emerge
- GM CFO Young: No Positive Cash Flow Until 2009
- Consumers' Mood Sours in Early July
- World Has Avoided Economic Disaster, Obama Says
- Less Demand for Fed's Emergency Backstops
- Claims Total Over 15,400 in Fraud by Madoff
- UBS Can't Comply with US Request: Internal Memo
- Cisco Cutting up to 2,000 Jobs, Analyst Says
- Treasury Sold Warrants Below Market Value: Panel
- Schork Oil Outlook: It’s Now or Never for the Bulls
- Social Networking's 'Naked' Truth
- Farrell: Let's Enjoy the Numbers for a Moment
- Call Of Shame - Vote Now
- Schmidt on Social Media, Ads and Hulu
- 15 Stocks to Consider
- Maximum Bob Goes Full Throttle For GM
- Najarian: Options Get Bullish on Cisco
- Sun Valley on Social Media
Eli Lilly Tuesday said U.S. regulators approved once-daily use of two low-dose forms of its Cialis anti-impotence drug, offering greater convenience for men expecting frequent sexual activity.
The Indianapolis drugmaker [LLY
Loading...
()
] said the once-daily formulations, in dosages of 2.5 milligrams and 5 milligrams, will allow men to attempt sexual activity any time between doses.
"In clinical trials, when taken without restrictions on the timing of sexual activity, Cialis for once daily use improved erectile function over the course of therapy," Lilly said in a release.
The low-dose daily formulations, already approved in parts of Europe, "may be most appropriate for men with erectile dysfunction who anticipate more frequent sexual activity (e.g. twice weekly)," Lilly said.
The company said the low-dose formulations provide "a new option for men who may be looking for a dosing option that can be taken without regard to timing of sexual activity."
The treatment, which has global annual sales of $1.2 billion, has been available in the United States since 2003 in dosages of 5 milligrams, 10 milligrams and 20 milligrams, and taken as needed. Those dosages provide effectiveness for up to 36 hours.
Company spokeswoman Keri McGrath said no dosage forms of the medicine, including the newly approved lower ones, are appropriate for heart patients who take nitrates, including nitroglycerin.
Members of the class of drugs to which Cialis belongs -- including Pfizer's [PFE
Loading...
()
] rival Viagra and GlaxoSmithKline's [GSK
Loading...
()
] Levitra -- can dangerously lower blood pressure when used alongside nitrates.
The drugs, used by millions of men worldwide, also carry new warnings about potential risk of sudden hearing loss.
Shares of Lilly were up $1.05, or 1.9 percent, to $55.60 in morning trading on the New York Stock Exchange, in line with a 2 percent advance for the drug sector.









